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ABSTRACT
We derived an ordinary differential equation model to capture the disease dynamics during blood-stage malaria. The model
was directly derived from an earlier age-structured partial differential equation model. The original model was simplified due to
experimental constraints. Here we calibrated the simplified model with experimental data using a multiple objective genetic
algorithm. Through the calibration process, we quantified the removal of healthy red blood cells and the the preferential infection
of reticulocytes during Plamodium cynomolgi infection of Macaca mulatta. The calibration of our model also revealed the
existence of host erythropoietic response prior to blood stage infection.
1 Introduction
The goal of this article is to quantify the removal of healthy red blood cells and preferential invasion of reticulocytes during
malaria infection, and find their associations with molecular phenomena through a modeling approach. The disease malaria
is caused by Plasmodium parasites. Out of the five human Plasmodium species capable of causing malaria, Plasmodium
falciparum and Plasmodium vivax account for the majority of human malaria infections. P. falciparum is responsible for the
majority of malaria-related mortality and is most prevalent in sub-Saharan Africa1.
The Plasmodium life cycle is comprised of several stages. The infection process in humans starts with the injection of
sporozoites by mosquitoes into the skin of the host. This is followed by the liver stage, during which the inoculated sporozoites
grow and multiply asexually within hepatocytes for 1-2 weeks to produce merozoites. The newly produced merozoites emerge
from the liver and enter the blood stream. The blood-stage infection starts immediately after the hepatic stage. The parasite’s
blood-stage infection in both human and non-human primates generally has a regular cycle of 24 to 72 hours depending on the
species of the Plasmodium parasite2, 3. The parasites invade healthy red blood cells (RBCs) and replicate asexually, remodeling
and ultimately destroying the RBCs in the process. The destruction of RBCs during blood-stage malaria infection sometimes
results in severe anemia, which is one of the major complications of malaria and a leading cause of mortality.
During blood-stage malaria infection, the majority of red blood cell loss has been attributed to the removal of healthy
red blood cells4–6. The hemodynamic model described by Yan et al7 characterizes this phenomenon through a mechanistic
model taking into account the interaction between healthy RBCs, infected RBCs, cells form the innate immune system, and
cells from the adaptive immune system. This model captures the clinical outcomes of a malaria infection: resistance to the
disease, susceptibility, and resilience (chronic infection with mild symptoms). That model has been simplified to account for
experimental constraints, and it has been calibrated in this article with the data of Macaca mulatta infected with P. cynomolgi
described by Joyner et al8. Plasmodium cynomolgi is a malaria parasite that infects old world monkeys; it is physiologically
and evolutionarily similar to P. vivax9, 10.
This paper is organized as follows: Section 2 provides the description of the experimental data. Section 3 contains the
detailed derivation and description of our hemodynamic model. Section 4 describes the model calibration process. Section 5
provides an overview of the calibration results. Section 6 integrates our modeling result with transcriptomic data collected during
the experiment. Section 7 describes an adjusted model based on our calibration results. Section 8 offers some conclusions, and
discusses the biological significance of our results.
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Figure 1. Parasite count over the entire experiment. Transcriptome, cytokine, and immune profiling were conducted during
the 6-time points marked with the red diamond. Subject S1 and S2 experienced severe malaria symptoms. Subject M1 and M2
experienced mild malaria symptoms.
The experimental design is shown in Fig 1. The infected red blood cell, total red blood cell, and reticulocyte concentration
were measured daily over the entire experiment. The four subjects, S1, S2, M1 and M2 are referred as Subject 1 ∼ 4 within
this paper. Each red diamond corresponds to a specific time point where transcriptome, cytokine and immune profiling was
conducted. Time point 2 (TP2) corresponds to the acute primary infection when parasite counts peaked. A detailed description
of the experiment that collected this data can be found in Joyner et al.8.
3 Matching a Theoretical Model with Experimental Constraints
The mechanistic partial differential equation model described by Yan et al.7, has the form presented below; the detailed
definition of variables, parameters and functions is presented in that paper, and also for completeness in the Appendix.
∂u
∂ t
+
∂u
∂a
=−
(
T
∑
i=1
wi(t)θi+
Q
∑
i=1
si(t)ψi+h(a)
)
u(a, t)
− γκv(αmax, t)p(u(a, t)),
∂v
∂ t
+V
∂v
∂α
=−
(
T
∑
i=1
wi(t)φi+
Q
∑
i=1
si(t)bi(t)
)
v(α, t),
dwi
dt
=oi(t)−βiwi(t),
dsi
dt
=li(t)−δisi(t),
(1)
subject to the following initial and boundary conditions:
u(a,0) =g(a),
u(0, t) = f (t,ϕ(t)),
v(α,0) =c(α),
v(0, t) =γκ
∫ amax
a0
v(αmax, t)p(u(a, t))da.
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With the experimental constraints, it was not possible to measure the delay in the erythropoietic response, and hence it was
removed from this model. Thus the boundary condition u(0, t) = x4ex5(T0−T (t)), where x4 is the baseline production of red blood
cells and x5 is a parameter controlling the speed of erythropoiesis response. T0 is the sum of the steady-state concentration of
reticulocytes and mature red blood cell and T is the sum of the concentration of reticulocytes and mature red blood cell at time
t.
Under the explicit assumption, that the immune cell populations do not interact with the infected red blood cell population
(v) and healthy red blood cell population (u) (φi = 0, θi = 0, ψi = 0, for all i and bi(t) = 0 for all t), the system reduces to:
∂u
∂ t
+
∂u
∂a
=−h(a)u(a, t)− γκv(αmax, t)p(u(a, t)),
∂v
∂ t
+V
∂v
∂α
=0.
Furthermore, under the explicit assumption that the initial age distribution of v is uniform, v(α,0) =C. Let
V (t) =
∫ αmax
0
v(α, t)dα,
where V (t) denote the total amount of iRBC at time t. Then,
V (0) = αmaxC.
Additionally, let t2 = t1 + ε,ε > 0, then:∫ αmax
0
v(α, t2)dα =
∫ αmax
0
v(α, t1)dα,
+
∫ t2
t1
γκ
∫ amax
a0
v(αmax, t)p(u(a, t))dadt,
−
∫ t2
t1
v(αmax, t)dt.
Because
∫ amax
a0 p(u(a, t)) = 1 for all t, the system further simplifies to:∫ αmax
0
v(α, t2)dα =
∫ αmax
0
v(α, t1)dα,
+
∫ t2
t1
γκv(αmax, t)dt,
−
∫ t2
t1
v(αmax, t)dt.
(2)
Substituting V into (2), and rearranging the equation:
V (t2)−V (t1) = (γκ−1)
∫ t2
t1
v(αmax, t)dt.
Thus, ∫ t2
t1
V˙ dt = (γκ−1)
∫ t2
t1
v(αmax, t)dt
and
V˙ = (γκ−1)
∫ amax
a0
v(αmax, t)p(u(a, t))da. (3)
Because the age distribution of red blood cells are unknown throughout the experiment, and only reticulocyte and mature red
blood cell populations are measured, we define a1 as the precise time point where reticulocytes become mature red blood cells.
We further define the total population of reticulocytes at time point t as R(t) and the total population of mature red blood cells
at time point t as U(t). R(t) and U(t) have the following form:
R(t) =
∫ a1
0
u(a, t)da,
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and
U(t) =
∫ amax
a1
u(a, t)da,
thus
R(t)+U(t) =
∫ amax
0
u(a, t)da.
Therefore, (3) can be rewritten as:
V˙ = (γκ−1)v(αmax, t)
(
R
R+U
+
U
R+U
)
.
Under the assumption that on average a small fixed percentage of infected red blood cells are bursting, then
v(αmax, t) =C2V.
Which means:
V˙ = (γκ−1)C2V
(
R
R+U
+
U
R+U
)
.
Additionally, knowing that the infection rate of reticulocyte is different from mature red blood cells, we can modify the system
to reflect this fact:
V˙ = (γκ1−1)C2V RR+U +(γκ2−1)C2V
U
R+U
.
Let
x3N = (γκ1−1)C2,
and
x6N = (γκ2−1)C2.
Then
V˙ = x3N
UV
R+U
+ x6N
RV
R+U
.
The derivative of R(t) can be derived similarly. Let:∫ a1
0
u(a, t2)da=
∫ a1
0
u(a, t1)da
+
∫ t2
t1
x4ex5(T0−T )dt
−
∫ t2
t1
u(a1, t)dt
−
∫ t2
t1
x6N
RV
R+U
.
Because the much shorter life span of reticulocytes in comparison to mature red blood cells11 and the fact that the survival
rate of reticulocytes to be close to 112, the hazard function, h(a), of reticulocyte is ignored. Substituting R, and rearrange the
equations, we obtain:
R(t2)−R(t1) =
∫ t2
t1
x4ex5(T0−T (t))−u(a1, t)− x6N RVR+U dt.
Thus,
R˙= x4ex5(T0−T )−u(a1, t)− x6N RVR+U .
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Under the assumption that on average a small fixed percentage of reticulocyte are aging into mature red blood cell at any given
time,
R˙= x4ex5(T0−T )− x1R− x6N RIR+U .
The derivative of U(t) is also derived similarly. let:∫ amax
a1
u(a, t2)da=
∫ amax
a1
u(a, t1)da
+
∫ t2
t1
u(a1, t)dt
−
∫ t2
t1
u(amax, t)dt.
−
∫ t2
t1
∫ amax
a1
h(a)u(a, t)dadt
−
∫ t2
t1
x3N
UV
R+U
.
Assuming that on average, a fixed percentage of red blood cells are removed due to random chance, substituting U then the
equation becomes:
U(t2)−U(t1) =
∫ t2
t1
u(a1, t)− x2U− x6N RIU+Rdt.
Thus:
U˙ = x1R− x2U− x6N RIU+R .
In conclusion, under the following explicit assumptions:
• The change of infected red blood cell population and healthy red blood cell population is independent of the immune cell
populations,
• the erythropoiesis response does not have a delay,
• on average, a fixed percentage of iRBCs are bursting at any given moment and a fixed percentage of reticulocytes are
transitioning into mature red blood cells,
the original PDE model (1) is simplified to the following system of ordinary differential equations that captures the change in
the total infected red blood cell, red blood cell, and reticulocyte population:
U˙ = x1R− x2U− x3NUIT ,
R˙= x4ex5(T0−T )− x1R− x6NRIT ,
I˙ = x3N
UI
U+R
+ x6N
RI
U+R
.
Where U denote the concentration of healthy mature red blood cells (RBCs), R denotes healthy reticulocytes (RT) and I denote
the concentration of infected red blood cells (iRBCs). Let T =U+R and T0 = R0 +U0 where R0 andU0 denote the steady state
concentration of RTs and RBCs in the absence of malaria infection. N denote the average merozoites produced per infected red
blood cell. x1R describes the aging of RTs to become RBCs. x2U denote the random removal of mature red blood cells. x3 and
x6 denote the infection success rate of RBCs and RTs respectively. x4 denotes the baseline production of RTs and the term
ex5(T0−T ) describes the host erythropoiesis response.
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4 Parameter Estimation
Under the assumption of steady state, where R0 is the steady state concentration of RTs and U0 is the steady state concentration
of RBCs, the following equality is established:
x4 = x1R0 = x2U0.
The average number of merozoite produced is set to be 20. Fonseca et al.12 estimated that the baseline production of RTs in M
mulatta, x4, is 192,00 cells per day12. R0 and U0 are estimated for each subjects using the average of the red blood cell and
reticulocytes counts during the first ten days of the experiment where no iRBCs were detected. The lower bound and upper
bound of the other three parameters, x3, x6 and x5 were also estimated. All three parameters are positive. The upper bound
of x5 was set to allow a maximum of 2-fold increase in RTs production in each subject. Upper bound of x3 and x6 was set to
be 0.05 and 1 respectively. When x3 > 0.05 and/or x6 > 1, the system becomes numerically unstable to solve due to stiffness
using odesolver45 in MATLAB environment. The upper bound of x3 and x6 also ensures that the I˙ < 0.5NI throughout the
simulation, meaning that the number of infected red blood cells produced over a two day period can not exceed the number of
merozoites produced.
A multiple objective genetic algorithm13 was used to estimate the parameters (x3,x6,x5) for each subjects using the estimated
lower and upper bound of each parameter. The model was fitted to the cellular data with starting date corresponding to the first
appearance of iRBCs and ending date corresponding to time point 2. The two objectives minimized were the average percent
error (APE) of predicted RTs and iRBCs concentration. APE have the following form for a specific variable such as RTs:
APEretic =
100
n
n
∑
i=1
ri−Ri
Ri
,
where ri is the observed RTs concentration at time point i and Ri is the model predicted RTs concentration. Contrary to single
objective minimization, a Pareto front for both objectives is estimated during each application of the genetic algorithm. The
Pareto front refers to a set of possible values of both object function such that the decrease in one objective function necessitates
the increase of the other13. Each application of a genetic algorithm is terminated when the change in the estimated Pareto front
is less than the predefined tolerance (0.0001). Due to the stochastic nature of the genetic algorithm, 1,000 runs were applied to
estimate the parameters for each subject. > 99% of the application of genetic algorithm terminated due to the convergence of
Pareto front, the rest did not converge during the maximum allowed run time of 60 seconds.
5 Results
5.1 Result Overview
The Pareto front of iRBC APE and RT APE for each subject are shown in Figure 2. For subject 1, 2 and 4, there exist a
sub-region on the Pareto front such that the iRBC APE and RT APE have a negative linear relationship, which means that
iRTAPE+RTAPE is close to constant. The Pareto front estimated for subject 3 does not contain such a region, indicating a
lack of model fit for that specific subject. The iRBC APE for all four subjects has a range of (45%∼ 90%) where the RT APE
have a range of (15%∼ 50%). The simulation of the top 100 model with the lowest iRBCs APE are shown in Figure (3, 4, 5,
6).
5.2 Quantification of The Preferential Infection of Reticulocyte by P. cynomolgi
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Figure 2. Estimated Pareto Front of Average Percentage Error (APE) of iRBCs and RTs for each of the four subjects.
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Figure 3. Simulation of the top 100 models with the lowest iRBCs APE and distribution of percent error of subject 1
To quantify the preferential infection of RTs by P cynomolgi, the ratio of x6 to x3 in the top 100 model with the lowest iRBCs
APE for each subject was calculated. The ratio x6x3 is interpreted as the likelihood of P cynomolgi infecting RTs over infecting
RBCs. The distribution of x6x3 is shown in Figure 7. The means of the four distribution are 13, 17, 28 and 18 respectively.
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Figure 4. Simulation of the top 100 models with the lowest iRBCs APE and distribution of percent error of subject 2
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Figure 5. Simulation of the top 100 models with the lowest iRBCs APE and distribution of percent error of subject 3
5.3 Quantification of Removal of Healthy Red Blood Cell (hRBC)
The loss of healthy RBC (hRBC) is also calculated based on the 100 model prediction with the lowest iRBC APE. Total Loss
of hRBC and Ratio of loss of hRBC and parasitized RBC are shown in Figure 8. On average, 1.5 million hRBCs per µl are
cleared by the host through out the onset of the disease till acute primary infection. Furthermore, our model predicted that for
each RBC parasitized, the host removes 3 hRBC. The quantification of the removal of hRBCs over the entire infection is shown
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Figure 7. Distribution of x6x3 for subjects 1 4.
in Figure 9. The model fit of RBC and retic Population after adjusting for removal of hRBCs are shown in Figure 10.
6 Correlation and Enrichment Analysis of Rate of hRBC Removal
The rate of hRBC removal was estimated for all four subjects (Fig 11) based on the estimated loss of hRBCs (Fig 9). Pearson’s
correlation between hRBC removal rate and their corresponding transcript, immune cell and cytokine abundance was calculated.
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Figure 9. Time series of estimated loss of hRBCs.
The p-value of the correlation was adjusted for false discovery rate and the transcript, immune cell and cytokine exhibiting
significant correlation with hRBC removal rate (q-val ≤ 0.05) are shown in Fig 12. Several pro-inflammatory ctokines such as
IL6 and IL1B are positively correlated with the rate of hRBC removal. On the other hand, CD8 T cell population displayed
significant negative correlation with hRBC removal rate.
Only seven genes: MYO3B, GAN, DNAJB4, TRIM45, TMEM150A, IL23R and BMF have shown significant correlation
with the rate of hRBC removal. To fully explore the association of transcriptome change and rate of hRBC removal, Gene
Set Enrichment Analysis14 was applied to the correlation ranked gene lists. The most significantly enriched GO gene sets
and pathways are shown in table 1 and table 2. Innate immune related gene sets and pathways are positively correlated with
hRBC removal rate, which corresponds to the positive correlation between hRBC removal and inflammatory cytokines. On the
other hand, transcripts that have negative correlation with hRBC removal are enriched in RNA and protein processing related
pathways.
10/17
2 4 6 8 10
15.4
15.5
15.6
15.7
Lo
g(
To
tal
 R
BC
)
1
2 4 6
15.45
15.5
15.55
15.6
15.65
2
2 4 6 8 10
Time
15.5
15.55
15.6
15.65
15.7
15.75
Lo
g(
To
tal
 R
BC
)
3
2 4 6 8 10
Time
15.55
15.6
15.65
15.7
15.75
15.8
4
Figure 10. Time series of model predicted total red blood cell adjusted by the mean of estimated loss of hRBC.
2 4 6 8 10
0
1
2
3
4
hR
B
C 
Re
m
ov
al
/D
ay
105 1
2 3 4 5 6 7
-1
0
1
2
3 10
5 2
2 4 6 8 10
Time
0
0.5
1
1.5
2
hR
B
C 
Re
m
ov
al
/D
ay
105 3
2 4 6 8 10
Time
0
0.5
1
1.5
2 10
5 4
Figure 11. Time series of model predicted hRBC removal rate for all four subjects.
7 Empirical Model Adjustment
The simulation of the top 100 model with the lowest iRBC APE for subject 1,2 and 3 (Figure 3, 4, 5, 6) failed to capture
the increase of RBC population during the early stages of malaria infection. Considering that the difference between RBC
population and steady state RBC population is minimal during the early stage of malaria infection, this discrepancy suggest that
RBCs are released during the early stage of blood stage malaria. Additionally, our correlation analysis identified several cell
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Table 1. Enrichment of GO Gene Sets
Positive Enriched GO Gene Sets Negative Enriched GO Gene Sets
INNATE IMMUNE RESPONSE NCRNA PROCESSING
IMMUNE EFFECTOR PROCESS NCRNA METABOLIC PROCESS
ACTIN FILAMENT BASED PROCESS RIBOSOME BIOGENESIS
REGULATION OF BODY FLUID LEVELS RRNA METABOLIC PROCESS
WOUND HEALING RIBONUCLEOPROTEIN COMPLEX BIOGENESIS
RESPONSE TO BACTERIUM TRANSLATIONAL INITIATION
DEFENSE RESPONSE TO OTHER ORGANISM AMIDE BIOSYNTHETIC PROCESS
INFLAMMATORY RESPONSE PEPTIDE METABOLIC PROCESS
ACTIVATION OF IMMUNE RESPONSE MULTI ORGANISM METABOLIC PROCESS
REGULATION OF RESPONSE TO WOUNDING NONSENSE MEDIATED DECAY
HEMOSTASIS PROTEIN LOCALIZATION
REGULATED EXOCYTOSIS PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM
SECRETION PROTEIN TARGETING TO MEMBRANE
RESPONSE TO WOUNDING TRNA METABOLIC PROCESS
CELLULAR RESPONSE TO NITROGEN COMPOUND RNA CATABOLIC PROCESS
ENDOCYTOSIS ORGANIC CYCLIC COMPOUND CATABOLIC PROCESS
RESPONSE TO VIRUS TRNA PROCESSING
CELL CELL ADHESION MITOCHONDRIAL TRANSLATION
REGULATION OF INFLAMMATORY RESPONSE TRANSLATIONAL ELONGATION
Table 2. Enrichment of Pathways
Positive Enriched Pathways Negative Enriched Pathways
SYSTEMIC LUPUS ERYTHEMATOSUS 3 UTR MEDIATED TRANSLATIONAL REGULATION
HEMOSTASIS TRANSLATION
CYTOKINE SIGNALING IN IMMUNE SYSTEM PEPTIDE CHAIN ELONGATION
CHEMOKINE SIGNALING PATHWAY RIBOSOME
INTERFERON ALPHA BETA SIGNALING INFLUENZA VIRAL REPLICATION
PID PDGFRB PATHWAY PROTEIN TARGETING TO MEMBRANE
REGULATION OF ACTIN CYTOSKELETON NONSENSE MEDIATED DECAY
PLATELET ACTIVATION SIGNALING AND AGGREGATION INFLUENZA LIFE CYCLE
AMYLOIDS METABOLISM OF PROTEINS
PID VEGFR1 2 PATHWAY METABOLISM OF RNA
RNA POL I PROMOTER OPENING FORMATION OF THE TERNARY COMPLEX
NABA MATRISOME ASSOCIATED ACTIVATION OF THE MRNA BINDING TO 43S
RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 METABOLISM OF MRNA
NABA SECRETED FACTORS MITOCHONDRIAL PROTEIN IMPORT
INTERFERON SIGNALING RNA POLYMERASE
RHO PATHWAY RNA POL III TRANSCRIPTION INITIATION
LEUKOCYTE TRANSENDOTHELIAL MIGRATION RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS
FOCAL ADHESION PYRIMIDINE METABOLISM
JAK STAT SIGNALING PATHWAY TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT
12/17
-1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1
Pearson's Correlation
BMF
TMEM150A
TRIM45
IL23R
CENTRAL MEMORY CD8  T CELLS
PD1  CENTRAL MEMORY CD8  T C
RBC
PLATELETS
HEMATOCRIT
HGB
CD8  T CELLS
GM CSF
G CSF
I TAC
PERC POSSIBLE RETIC PROGENIT
IL 6
SDF 1 ALPHA
IL 12P70
TGF BETA
NGF BETA
PARASITES
IL 4
IL 7
PERC PARASITES
MCP 3
MIP 1 BETA
IP 10
IL 12P40
MIP 1 ALPHA
IL 23
IL 5
TNF ALPHA
IL 1 BETA
TRAIL
TGF ALPHA
BLC
MIG
IL 2
IL 17A
GAN
MYO3B
DNAJB4
Figure 12. Transcripts, immune cell population and cytokines that are highly correlated (q-val ≤ 0.05) with hRBC removal
rate.
types, cytokines and transcripts (q-value ≤ 0.05) that are linearly correlated with hRBC removal rate. This finding suggest the
possibility of using these entities to predict hRBC removal rate. Taking these findings into consideration, our original model
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can be further expanded to:
U˙ = x1R− x2U− x3NUIT −∑γiEi+g(M),
R˙= x4ex5(T0−T )− x1R− x6NRIT ,
I˙ = x3N
UI
U+R
+ x6N
RI
U+R
,
is linearly explained by a combination of the abundances of inflammatory cytokines. Where each Ei denote the abundance of a
cytokine exhibiting linear correlation with the rate of hRBC removal (Fig: 12) and each γi quantifies the linear dependency.
The term g(M) denote the increase of RBC population during the early stage of malaria infection, that is dependent on some
molecular quantity M, possibly pathogen related. The estimated form of g(M) are shown in Figure 13 and the post-hoc fitted
model is shown in Figure 14.
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Figure 13. Time series of g(M) for subject 1 through 4.
8 Discussion
In this chapter, a simplified Ordinary Differential Equation model was fitted to the time series data collected from the MaHPIC
experiment. Our simplified model was derived from the earlier PDE system under three explicit assumptions. The simplification
of the original model reduced the unknown parameters to 3 parameters with well-defined lower and upper bounds.
The model was fitted using multiple objective genetic algorithm and the Pareto front estimated (Fig: 2) demonstrate that the
simplified model describes the dynamics of RTs much better than that of iRBCs as shown by the 2-fold difference in the range
of RT APE and iRBC APE. The iRBC APE for all four subjects has a range of (45%∼ 90%) where as the RT APE have a
range of (15%∼ 20%). This result suggests that the immune function omitted in our model have a large impact on parasite
population during the primary infection.
The best-fitted models were used to quantify the preferential infection of RTs by P. cynomolgi. Our model predicts that, on
average, P. cynomolgi merozoites are 20 times more likely to infect RTs than RBC (Fig 7). The experimental verification of our
prediction is difficult due to the lack of an in vitro system to study P. cynomolgi, but our prediction provides a general range of
preferential infection of RTs, which can be utilized in future experimental designs and modeling studies.
Additionally, in all the best fit models (Fig 3, 4, 5, 6), our prediction of RBC concentration and RT concentration are higher
than observed. This over estimation of RBC and RT concentration constitutes the majority of APE. Furthermore, our iRBC
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Figure 14. Final adjusted model prediction of RBC population for subjects 1 through 4.
concentration predictions are on average lower than the observed value. We utilized this fact to estimate the lower bound of the
amount of hRBCs removed by the host. Our model estimates that at least 50%∼ 80% of RBC loss during the primary infection
of P. cynomolgi are due to the removal of hRBCs 8. Finally, our model shows that the speed at which hRBCs are removed
increases throughout the infection.
Using the estimated hRBC removal rate, a correlation study was conducted to identify transcript, immune cell and cytokine
abundance that has significant correlation with hRBC removal rate. Interestingly, innate immune related gene sets (Interferon
Response, Rho Pathway and JAK-STAT pathway et al.) along with pro-inflammatory cytokines (IL-1B, IL-6 et al.) displayed
significant positive correlation with hRBC removal. The association of severe malaria anemia with pro-inflammatory response
has long been studied15; our analysis provides a list of possible cytokine biomarkers for the estimation of host clearance of
hRBCs. Due to the experimental constraint where cytokine profiling was only conducted during peak parasitemia, our analysis
lacks the resolution to provide a mechanistic explanation for the correlation between pro-inflammatory cytokines and host
removal of hRBC. Furthermore, the observation that inflammation related genes and cytokines are differentially up-regulated in
the severe subjects (Subject 1 and 2), along with the fact that severe subjects have a higher rate of hRBC removal during peak
parastemia, suggest the possible role of inflammation associated hRBC clearance and clinical severity.
In conclusion, we have demonstrated that a simplified model with only three unknown parameters can be used to predict RT
concentration with an APE of (15%∼ 20%). Despite the model’s relatively poor performance at predicting iRBC dynamics
(APE 50%∼ 70%), it can be used to estimate the preferential infection of RTs and hRBC removal during malaria infection.
The estimation of the hRBC removal rate using our model along with the down-stream enrichment analysis reveals associations
of hRBC removal and both the inflammatory response and CD 8 T-cell response. Application of this model to more time series
data sets of malaria infection involving a variety of malaria species is necessary to validate our findings.
15/17
APPENDIX
The parameters, functions, and variables described by Yan et al.7 are presented here for completeness. The reader is encouraged
to read that article for a detailed description of each element.
Description Unit
Independent Variables
t Time. Day
a Age of RBC. Day
α Age of iRBC. 10−1Day
Dependent Variables
u(a, t) Circulating RBC age distribution. cells/ul/day
v(α, t) iRBC age distribution. cells/ul/day
ϕ(t) Circulating RBC concentration. cells/ul
wi(t) Circulating innate immune cell concentration. cells/ul
si(t) Circulating adaptive immune cell concentration. cells/ul
Functions
h(a) Percentage of RBC that leaves circulation per day,
usually a constant.
1/day
f (t,ϕt ) Rate at which RBC enters circulation. cells/ul/day
r(a) Success rate of merozoite invading RBC of age. a 1/day
p(u(a, t)) Probability of a merozoite infecting a RBC of age.
a at time t
dimensionless
bi(t) Rate at which adaptive immunity cell i destroys
iRBC.
1/(day · cells/ul)
oi(t) Rate at which innate immune cell enters circula-
tion.
cells/ul/day
li(t) Rate at which adaptive immune cell enters circula-
tion.
cells/ul/day
Description Unit
Parameters
V Speed at which parasite ages, equal to 1/α . 1/(day)
ϕ0 Normal circulating RBC concentration, equal to
ϕ(0).
cells/ul
γ Average number of merozoite produced by a single
iRBC.
dimensionless
θi Rate at which innate immunity cell i destroys RBC. 1/(day · cells/ul)
ψi Rate at which adaptive immunity cell i destroys
RBC.
1/(day · cells/ul)
φi Rate at which innate immunity cell i destroys
iRBC.
1/(day · cells/ul)
βi Rate at which innate immunity cell decays. 1/day
δi Rate at which adaptive immunity cell decays. 1/day
τi Rate at which innate immunity cell decay due to
contact with iRBC.
1/(day · cells/ul)
ϑi Rate at which adaptive immunity cell decay due to
contact with iRBC.
1/(day · cells/ul)
λi Coefficient for change of adaptive immunity effec-
tor strength.
1/cells/ul
ϖi Normal rate of production of innate immune cell i. cells/ul/day
σi Normal rate of production of adaptive immune cell
i.
cells/ul/day
εi Maximum rate of production of innate immune cell
i.
cells/ul/day
ρi Maximum rate of production of adaptive immune
cell i.
cells/ul/day
νi Maximum adaptive immunity effector i strength. 1/day/cells/ul
ηi Coefficient for change of production of innate im-
mune cell i.
1/cells/ul
ωi Coefficient for change of production of adaptive im-
mune cell i.
1/cells/ul
Mi Amount of parasite where the production of innate
immune cell i. increase the most
cells/ul
Ri Amount of parasite where the production of adap-
tive immune cell i. increase the most
cells/ul
xii Amount of parasite where the production of adap-
tive immune cell i. effector strength increase the
most
cells/ul
ε Coefficient for change of erythropoiesis. 1/cells/ul
ς Number of RBC entering blood stream. cells/ul/day
Td Delay of hematopoietic response. day
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